News
Novo Nordisk abruptly ended its partnership with Hims & Hers after the Danish drugmaker accused the telehealth company of ...
The breakup between Hims & Hers and Novo Nordisk has hit HIMS stock hard with a 35% crash. Click here for a full investment ...
The loss of its ability to sell Wegovy is a significant hit to Hims & Hers' business. The massive drop today in its stock ...
First, the stock has sliced through two support levels. Shares broke through their 50-day moving average on Monday for the ...
Zacks.com users have recently been watching Hims & Hers Health (HIMS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Novo Nordisk had been providing Hims & Hers with the FDA-approved Wegovy, an injectable semaglutide used for weight loss ...
The companies engaged in an increasingly heated war of words on Monday following the drugmaker's decision to end a collaboration.
MarketBeat on MSN1d
Why Hims & Hers Stock Could Be a Multi-Bagger in the MakingIt’s not often that investors come across the kind of companies that can yield a multi-bagger investment over the years.
Novo Nordisk has announced it is ending its distribution collaboration with US telehealth firm Hims & Hers Health over the ...
Hims & Hers Health (NASDAQ: HIMS) experienced a devastating 35% stock crash on June 23, 2025, after Novo Nordisk abruptly terminated their brief partnership. The dramatic sell-off reflects not ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback